Marina Yuryevna Dorofeyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Yuryevna Dorofeyeva has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina E. Zelenova
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
4 shared publications - Elena V. Sharapova
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
4 shared publications - Svetlana R. Varfolomeeva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
4 shared publications - Tatiana S. Belysheva
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
4 shared publications - Tatiana V. Nasedkina
Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences, 119991 Moscow, Russia
4 shared publications - Timur Teimurazovich Valiev
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
4 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9889
Clinical Features, Genetics and Treatment in a Russian Cohort of Young Patients with Xeroderma Pigmentosum: A Single Center Experience
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 6–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified patients with homozygous or compound heterozygous variants in XPC (n = 8), XPA (n = 4), DDB2 (n = 1), and ERCC6 (n = 1). Two XP and one CS cases were presented in one family. A total of 110 relatives were screened to determine carrier status. Skin cancer was revealed in 100% of the 13 XP patients; the median age at first manifestation was 13 years (range 5–23). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 7, and 3 patients, respectively. All three cancer types occurred in two patients. The patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered successfully in three patients with multiple or advanced skin tumors.
- 4 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9889
Open AccessClinical Features, Genetics and Treatment in a Russian Cohort of Young Patients with Xeroderma Pigmentosum: A Single Center Experience
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 6–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified patients with homozygous or compound heterozygous variants in XPC (n = 8), XPA (n = 4), DDB2 (n = 1), and ERCC6 (n = 1). Two XP and one CS cases were presented in one family. A total of 110 relatives were screened to determine carrier status. Skin cancer was revealed in 100% of the 13 XP patients; the median age at first manifestation was 13 years (range 5–23). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 7, and 3 patients, respectively. All three cancer types occurred in two patients. The patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered successfully in three patients with multiple or advanced skin tumors.
- Open Access
- 27 August 2026
- Published by MDPI AG in Preprints.org
Clinics, Genetics and Treatment in a Russian Cohort of Young Patients with Xeroderma Pigmentosum: A Single Center Experience
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV-radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 5–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified homozygous or compound heterozygous variants in XPC (8 patients) and XPA (3 patients). In one family with two XP cases, a patient with CS and compound heterozygous ERCC6 variants was identified. In total, 110 family members were screened to determine their carrier status. Skin cancer was revealed in 12/13 (92%) of XP patients, with a median age at diagnosis of 12.5 years (range 5–22). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 6, and 3 patients, respectively. All three cancer types occurred in 2 patients. All patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered with a favorable clinical response in three patients with advanced SCC or melanoma.
- 27 August 2026
- Published by MDPI AG in Preprints.org
Open AccessClinics, Genetics and Treatment in a Russian Cohort of Young Patients with Xeroderma Pigmentosum: A Single Center Experience
Xeroderma pigmentosum (XP) and Cockayne syndrome (CS) are rare autosomal recessive DNA repair disorders. XP is characterized by extreme sensitivity to UV-radiation and a very high risk of skin cancer. To date, little is known about the clinical characteristics and genetic basis of these diseases in Russia. Here, we present a detailed study of 14 patients (aged 5–30 years) from 11 unrelated families of diverse ethnic backgrounds. Using a multigene panel or whole-genome sequencing, we identified homozygous or compound heterozygous variants in XPC (8 patients) and XPA (3 patients). In one family with two XP cases, a patient with CS and compound heterozygous ERCC6 variants was identified. In total, 110 family members were screened to determine their carrier status. Skin cancer was revealed in 12/13 (92%) of XP patients, with a median age at diagnosis of 12.5 years (range 5–22). Basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma developed in 10, 6, and 3 patients, respectively. All three cancer types occurred in 2 patients. All patients underwent surgical treatment; additionally, two patients with BCC received targeted therapy (vismodegib, sonidegib). Anti-PD-1 immunotherapy was administered with a favorable clinical response in three patients with advanced SCC or melanoma.
- Open Access
- 19 August 2026
- Published by MDPI AG in Preprints.org
Mosaic RASopathies: Comprehensive Genetic and Clinicopathological Analysis for Diagnosis and Management
Mosaic RASopathies are rare conditions caused by postzygotic mutations in RAS/MAPK signaling pathway genes arising during embryonic development. They are mainly characterized by a combination of epidermal nevi with extra-cutaneous manifestations. Choosing between different entities can be challenging because of their substantial clinical and genetic overlap. Our aim was to demonstrate the importance of genetic background in accurate diagnosis and further prognostic assessment of disease progression by analyzing genotype–phenotype correlations within this clinical group. The study enrolled 18 patients (10 males, 8 females) aged from 1 month to 21 years with congenital nevi of craniofacial localization and variable extracutaneous abnormalities. DNA isolated from peripheral blood lymphocytes and affected tissues (nevus, tumor) was analyzed using a targeted next-generation sequencing (NGS) panel covering RAS/MAPK pathway genes, followed by Sanger sequencing. Eight patients were diagnosed with Schimmelpenning–Feuerstein–Mims syndrome caused by postzygotic mutations in the HRAS (n=4) or KRAS (n=4) genes. Seven patients were clinically diagnosed with phacomatosis pigmentokeratotica, and mosaic mutations were identified in the HRAS (n=4), KRAS (n=2), or BRAF (n=1) genes. Two patients with similar phenotypes carried somatic mutations in the PIK3CA and FGFR2 genes, respectively, and in one case no mutation was detected in the affected skin. We compared the spectrum of extracutaneous anomalies depending on the mutation in a specific gene by combining our data with data from other clinical cases of mosaic RASopathies described in the literature. In summary, 53 cases with HRAS postzygotic mutations and 41 cases with KRAS mutations were involved in the analysis of genotype–phenotype correlations. Hypophosphatemic rickets and malignant tumors were associated with mutations in the HRAS gene, while ophthalmological, neurological, cardiovascular, and renal disorders were more common in KRAS-mutant patients. Thus, genetic testing of affected tissue is essential for accurate diagnosis of these mosaic disorders. Taking into account clinical manifestations and the identified genotype–phenotype correlations may further assist in prognosis and patient management.
- 19 August 2026
- Published by MDPI AG in Preprints.org
Open AccessMosaic RASopathies: Comprehensive Genetic and Clinicopathological Analysis for Diagnosis and Management
Mosaic RASopathies are rare conditions caused by postzygotic mutations in RAS/MAPK signaling pathway genes arising during embryonic development. They are mainly characterized by a combination of epidermal nevi with extra-cutaneous manifestations. Choosing between different entities can be challenging because of their substantial clinical and genetic overlap. Our aim was to demonstrate the importance of genetic background in accurate diagnosis and further prognostic assessment of disease progression by analyzing genotype–phenotype correlations within this clinical group. The study enrolled 18 patients (10 males, 8 females) aged from 1 month to 21 years with congenital nevi of craniofacial localization and variable extracutaneous abnormalities. DNA isolated from peripheral blood lymphocytes and affected tissues (nevus, tumor) was analyzed using a targeted next-generation sequencing (NGS) panel covering RAS/MAPK pathway genes, followed by Sanger sequencing. Eight patients were diagnosed with Schimmelpenning–Feuerstein–Mims syndrome caused by postzygotic mutations in the HRAS (n=4) or KRAS (n=4) genes. Seven patients were clinically diagnosed with phacomatosis pigmentokeratotica, and mosaic mutations were identified in the HRAS (n=4), KRAS (n=2), or BRAF (n=1) genes. Two patients with similar phenotypes carried somatic mutations in the PIK3CA and FGFR2 genes, respectively, and in one case no mutation was detected in the affected skin. We compared the spectrum of extracutaneous anomalies depending on the mutation in a specific gene by combining our data with data from other clinical cases of mosaic RASopathies described in the literature. In summary, 53 cases with HRAS postzygotic mutations and 41 cases with KRAS mutations were involved in the analysis of genotype–phenotype correlations. Hypophosphatemic rickets and malignant tumors were associated with mutations in the HRAS gene, while ophthalmological, neurological, cardiovascular, and renal disorders were more common in KRAS-mutant patients. Thus, genetic testing of affected tissue is essential for accurate diagnosis of these mosaic disorders. Taking into account clinical manifestations and the identified genotype–phenotype correlations may further assist in prognosis and patient management.
- Open Access
- 19 December 2025
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (3) , 41-54
Epilepsy and attention-deficit/hyperactivity disorder. Problems of antiepileptic therapy
This review is based on the consensus statement of the International League Against Epilepsy’s pediatric panel on the diagnosis and management of patients with epilepsy and attention-deficit/hyperactivity disorder (ADHD). The document has been expanded and supplemented by later publications. Its main provisions: ADHD is 3–5 times more common in children with epilepsy than in the general population; the risk of developing epilepsy in people with ADHD is also increased. No gender differences were found in the manifestations of ADHD in boys and girls with epilepsy. Taking valproate during pregnancy increases the risk of developing ADHD in the child. The presence of intellectual and developmental disabilities, as well as poor seizure control, increase the risk of developing ADHD. Screening for ADHD should be performed in all children with epilepsy, beginning at age 6, when the diagnosis of epilepsy is established. Children should be retested annually for ADHD symptoms, including after a change in antiepileptic medication. The International League Against Epilepsy recommends the Strengths and Difficulties Questionnaire for ADHD screening. Behavioral problems occur more frequently with polytherapy than with monotherapy. A number of antiepileptic drugs (for example, valproate, benzodiazepines, etc.) can worsen cognitive and behavioral problems in patients with epilepsy and ADHD. Sulthiame has good cognitive tolerability and is approved for the treatment of hyperkinetic behavior and behavioral disorders in epilepsy, making it the drug of choice for patients with epilepsy and behavioral disorders, such as ADHD.
- 19 December 2025
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 20 (3) , 41-54
Open AccessEpilepsy and attention-deficit/hyperactivity disorder. Problems of antiepileptic therapy
This review is based on the consensus statement of the International League Against Epilepsy’s pediatric panel on the diagnosis and management of patients with epilepsy and attention-deficit/hyperactivity disorder (ADHD). The document has been expanded and supplemented by later publications. Its main provisions: ADHD is 3–5 times more common in children with epilepsy than in the general population; the risk of developing epilepsy in people with ADHD is also increased. No gender differences were found in the manifestations of ADHD in boys and girls with epilepsy. Taking valproate during pregnancy increases the risk of developing ADHD in the child. The presence of intellectual and developmental disabilities, as well as poor seizure control, increase the risk of developing ADHD. Screening for ADHD should be performed in all children with epilepsy, beginning at age 6, when the diagnosis of epilepsy is established. Children should be retested annually for ADHD symptoms, including after a change in antiepileptic medication. The International League Against Epilepsy recommends the Strengths and Difficulties Questionnaire for ADHD screening. Behavioral problems occur more frequently with polytherapy than with monotherapy. A number of antiepileptic drugs (for example, valproate, benzodiazepines, etc.) can worsen cognitive and behavioral problems in patients with epilepsy and ADHD. Sulthiame has good cognitive tolerability and is approved for the treatment of hyperkinetic behavior and behavioral disorders in epilepsy, making it the drug of choice for patients with epilepsy and behavioral disorders, such as ADHD.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 120-125
Mosaic neurofibromatosis type 1 in a 13-year-old child: description of a clinical case
Neurofibromatosis type 1 (NF1) is an autosomal dominant, highly penetrant disorder caused by pathogenic variants (mutations) in the NF1 gene. Mosaic NF1 is a distinct form of this disorder. Somatic mosaicism in NF1 is a rare condition caused by postzygotic pathogenic variants in the NF1 gene. The article presents a clinical case of mosaic NF1 in a 13-year-old child.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 120-125
Open AccessMosaic neurofibromatosis type 1 in a 13-year-old child: description of a clinical case
Neurofibromatosis type 1 (NF1) is an autosomal dominant, highly penetrant disorder caused by pathogenic variants (mutations) in the NF1 gene. Mosaic NF1 is a distinct form of this disorder. Somatic mosaicism in NF1 is a rare condition caused by postzygotic pathogenic variants in the NF1 gene. The article presents a clinical case of mosaic NF1 in a 13-year-old child.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 103-116
Modern approaches to the diagnosis and treatment of Dravet syndrome in the Russian Federation. (Literature review and resolution of the Expert Council)
Dravet syndrome (DS) is a rare genetic disorder with onset at 1 year of age, one of the most severe forms of epilepsy, which is characterized by a high frequency and severity of seizures, impaired psychoneurological development, disability and high mortality. Timely diagnosis and treatment can significantly alleviate the course of DS and improve the quality of life of patients and their families. Currently, there is an urgent need to increase awareness of pediatric neurologists and primary care physicians about the diagnostic criteria for the timely detection of patients with DS, referral to an epileptologist to confirm the diagnosis and prescribe the necessary therapy. The provisions of the Expert Council’s resolution, which took place on March 14, 2025, are presented.
- Open Access
- 18 September 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (4) , 305-313
Phacomatosis Pigmentokeratotica: Case Study
Background. Phacomatosis pigmentokeratotica (PPK) is an orphan genodermatosis from the epidermal nevus syndrome group. This disease is caused by somatic mosaicism predominantly in the HRAS gene. Pathognomonic PPK sign is combination of congenital linear nevus sebaceus of Jadassohn and speckled lentiginous nevus. Second one may debut much later. In some cases, there are signs of nervous system damages, skeletal disorders, visual impairments. Case description. Description of a patient with PPK and novel for this disease mosaic variant G469A in the BRAF gene is presented. Clinical picture included typical signs of the syndrome and immunological disorders unusual for patients with PPK. Possible genotype-phenotype correlations were analyzed based on 16 previously published observations of genetically verified PPK. Conclusion. The syndrome rarity, its course variability, and patients genetic testing features determine the difficulties in PPK diagnosis. The disease should be considered not only in terms of dermatological signs, but also regarding comorbid disorders. The dynamic follow-up should include consultations of pediatric oncologist, neurologist, ophthalmologist, endocrinologist, orthopedist, cardiologist, and immunologist.
- 18 September 2025
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 24 (4) , 305-313
Open AccessPhacomatosis Pigmentokeratotica: Case Study
Background. Phacomatosis pigmentokeratotica (PPK) is an orphan genodermatosis from the epidermal nevus syndrome group. This disease is caused by somatic mosaicism predominantly in the HRAS gene. Pathognomonic PPK sign is combination of congenital linear nevus sebaceus of Jadassohn and speckled lentiginous nevus. Second one may debut much later. In some cases, there are signs of nervous system damages, skeletal disorders, visual impairments. Case description. Description of a patient with PPK and novel for this disease mosaic variant G469A in the BRAF gene is presented. Clinical picture included typical signs of the syndrome and immunological disorders unusual for patients with PPK. Possible genotype-phenotype correlations were analyzed based on 16 previously published observations of genetically verified PPK. Conclusion. The syndrome rarity, its course variability, and patients genetic testing features determine the difficulties in PPK diagnosis. The disease should be considered not only in terms of dermatological signs, but also regarding comorbid disorders. The dynamic follow-up should include consultations of pediatric oncologist, neurologist, ophthalmologist, endocrinologist, orthopedist, cardiologist, and immunologist.
- Open Access
- 15 July 2025
- Published by ECO-Vector LLC in Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care
- Vol. 15 (2) , 181-192
Surgical Treatment of Children with Neurofibromatosis Type 1: a Case Series
BACKGROUND: Among hereditary diseases predisposing individuals to tumor development, neurofibromatosis type 1 ranks among the most prevalent. Due to the heterogeneity of clinical symptoms typical for this condition, patients often consult various specialists, which objectively leads to underestimation of symptoms and delayed diagnosis. AIM: This study aimed to perform a comparative analysis of diagnostic approaches and surgical treatment in patients with this disease given the rarity of the disease and the lack of unified management protocols for neurofibromatosis type 1 in Russia to date. METHODS: A retrospective analysis was conducted on clinical data from 20 pediatric patients who underwent surgical treatment for neurofibromatosis type 1 at the Yu.E. Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery. RESULTS: Clinical records of 20 children (9 boys and 11 girls) were reviewed. The median age at the time of diagnosis was 7 years (1 to 17 years). In most patients (n = 15), neurofibromatosis type 1 manifestations were located in the head and neck region. The absence of a standardized diagnostic protocol for children with suspected neurofibromatosis was noted: magnetic resonance imaging of the affected area was performed in 19 patients, whereas brain magnetic resonance imaging and abdominal ultrasound were conducted in only one-third of the patients. In total, 36 surgeries were performed. The presence of a mass was the indication for surgery in 20 cases. In 3 patients with neurofibromas, initial histological diagnosis was incorrect, resulting in delayed diagnosis and inappropriate treatment strategies. Tumor recurrence was observed in 14 of the 26 cases following complete excision, which necessitated repeat surgical interventions (n = 9). A rare case of intestinal ganglioneurofibromatosis is also presented. CONCLUSION: Variability in clinical manifestations, the rarity of the condition, and a general lack of awareness among pediatric surgeons often result in delayed diagnosis and inadequate treatment. Children were assessed and managed by various specialists without a systematic approach, and often underwent surgery without consideration of the pathogenesis of their condition. The creation of a clinical registry for such patients, as well as the establishment of multidisciplinary medical teams, with treatment decisions for children with neurofibromatosis type 1 made exclusively through case conferences, is of great importance.
- 15 July 2025
- Published by ECO-Vector LLC in Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care
- Vol. 15 (2) , 181-192
Open AccessSurgical Treatment of Children with Neurofibromatosis Type 1: a Case Series
BACKGROUND: Among hereditary diseases predisposing individuals to tumor development, neurofibromatosis type 1 ranks among the most prevalent. Due to the heterogeneity of clinical symptoms typical for this condition, patients often consult various specialists, which objectively leads to underestimation of symptoms and delayed diagnosis. AIM: This study aimed to perform a comparative analysis of diagnostic approaches and surgical treatment in patients with this disease given the rarity of the disease and the lack of unified management protocols for neurofibromatosis type 1 in Russia to date. METHODS: A retrospective analysis was conducted on clinical data from 20 pediatric patients who underwent surgical treatment for neurofibromatosis type 1 at the Yu.E. Veltishchev Research Clinical Institute of Pediatrics and Pediatric Surgery. RESULTS: Clinical records of 20 children (9 boys and 11 girls) were reviewed. The median age at the time of diagnosis was 7 years (1 to 17 years). In most patients (n = 15), neurofibromatosis type 1 manifestations were located in the head and neck region. The absence of a standardized diagnostic protocol for children with suspected neurofibromatosis was noted: magnetic resonance imaging of the affected area was performed in 19 patients, whereas brain magnetic resonance imaging and abdominal ultrasound were conducted in only one-third of the patients. In total, 36 surgeries were performed. The presence of a mass was the indication for surgery in 20 cases. In 3 patients with neurofibromas, initial histological diagnosis was incorrect, resulting in delayed diagnosis and inappropriate treatment strategies. Tumor recurrence was observed in 14 of the 26 cases following complete excision, which necessitated repeat surgical interventions (n = 9). A rare case of intestinal ganglioneurofibromatosis is also presented. CONCLUSION: Variability in clinical manifestations, the rarity of the condition, and a general lack of awareness among pediatric surgeons often result in delayed diagnosis and inadequate treatment. Children were assessed and managed by various specialists without a systematic approach, and often underwent surgery without consideration of the pathogenesis of their condition. The creation of a clinical registry for such patients, as well as the establishment of multidisciplinary medical teams, with treatment decisions for children with neurofibromatosis type 1 made exclusively through case conferences, is of great importance.
- 30 May 2025
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 89 (3) , 17-27
Surgical treatment of epilepsy associated with tuberous sclerosis in children: a single-center retrospective study
Background. The most common symptom of CNS damage in tuberous sclerosis is epilepsy. The last one is drug-resistant in most cases. Surgical treatment should be considered in these patients. Objective. To analyze the results of surgical treatment of drug-resistant epilepsy in children with tuberous sclerosis, to identify predictors of successful treatment. Material and methods. A retrospective study included 45 children between 2017 and 2023. In addition to standard non-invasive procedures, preoperative management included stereo-EEG in 19 cases, subdural EEG in 2 cases and staged subdural and stereo-EEG in 1 case. Selective tuberectomy was performed in 15 patients, tuberectomy (+) — in 16 children, lobectomy — in 6, multilobar resection — in 4, posterior quadrant disconnection — in 2, hemisphrotomy — in 2, repeated surgeries — in 6 children. Results. The median follow-up was 27 months. Postoperative outcomes ILAE grade I, IV, V and VI were observed in 62%, 25%, 11% and 2% of cases, respectively. Antiepileptic therapy was discontinued in 4.4% of cases. In 22.2% of patients, doses of drugs were reduced. Epileptogenic zone in frontal lobe favorably affected postoperative outcome (p=0.027). Transient hemiparesis occurred in 5 (11.1%) cases, persistent expected hemiparesis — in 1 (2.2%) case. Conclusion. Surgical treatment is effective for epilepsy in children with tuberous sclerosis. It is advisable to refer children with epilepsy and tuberous sclerosis to specialized centers for preoperative examination if therapy with two drugs is ineffective.
- 30 May 2025
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 89 (3) , 17-27
Surgical treatment of epilepsy associated with tuberous sclerosis in children: a single-center retrospective study
Background. The most common symptom of CNS damage in tuberous sclerosis is epilepsy. The last one is drug-resistant in most cases. Surgical treatment should be considered in these patients. Objective. To analyze the results of surgical treatment of drug-resistant epilepsy in children with tuberous sclerosis, to identify predictors of successful treatment. Material and methods. A retrospective study included 45 children between 2017 and 2023. In addition to standard non-invasive procedures, preoperative management included stereo-EEG in 19 cases, subdural EEG in 2 cases and staged subdural and stereo-EEG in 1 case. Selective tuberectomy was performed in 15 patients, tuberectomy (+) — in 16 children, lobectomy — in 6, multilobar resection — in 4, posterior quadrant disconnection — in 2, hemisphrotomy — in 2, repeated surgeries — in 6 children. Results. The median follow-up was 27 months. Postoperative outcomes ILAE grade I, IV, V and VI were observed in 62%, 25%, 11% and 2% of cases, respectively. Antiepileptic therapy was discontinued in 4.4% of cases. In 22.2% of patients, doses of drugs were reduced. Epileptogenic zone in frontal lobe favorably affected postoperative outcome (p=0.027). Transient hemiparesis occurred in 5 (11.1%) cases, persistent expected hemiparesis — in 1 (2.2%) case. Conclusion. Surgical treatment is effective for epilepsy in children with tuberous sclerosis. It is advisable to refer children with epilepsy and tuberous sclerosis to specialized centers for preoperative examination if therapy with two drugs is ineffective.
- Open Access
- 1 March 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (3) , e240184
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary
What is this summary about?: Neurofibromatosis type 1 (also called NF1) is a rare genetic condition. It causes a range of symptoms that develop from childhood onwards and worsen over time. Some children with NF1 develop non-cancerous nerve tumors called plexiform neurofibromas. Plexiform neurofibromas can grow large and compress nearby tissues. This can cause severe pain, reduced movement, vision and hearing loss, and other medical problems. Some children can have plexiform neurofibromas removed surgically. Most children have tumors that cannot be removed by surgery (known as inoperable tumors). Children with inoperable plexiform neurofibromas can receive a medicine called selumetinib. This plain language summary includes important findings from two selumetinib studies in children with NF1 and inoperable plexiform neurofibromas: The SPRINT selumetinib studies are part of a clinical study program that looked at how well selumetinib works in treating children with symptomatic, inoperable plexiform neurofibromas. The SPRINT studies program included the first studies of this medicine done in children, called phase 1 and phase 2 studies. For the phase 2 study, some children had severe symptoms and some children did not. The group of children with severe symptoms is called group 1, and their results are included in this summary. The researchers monitored the participating children for up to 5 years in a long-term study to better understand how the treatment works over time. The NF1 caregivers experience study is a related study where caregivers shared their experiences of caring for children with NF1and plexiform neurofibromas. What were the results?: A total of 74 children took part in the SPRINT phase 1 and phase 2 (group 1) study. Their ages ranged from 3 to 18.5 years, and their average age was 10.3 years. After more than 4 years of treatment, around 70% of the children (52 out of 74) had smaller tumors. For most children, the responses lasted beyond 1 year. There was a significant and lasting reduction in the intensity of the children’;s tumor pain, noticeable as early as 2 months after starting the treatment. After 12 months, children reported their pain dropped from an average score of 2.2 to 0.6 and stayed low at 0.58 over 4 years. There was also an improvement in how much their pain affected the children's ability to do daily tasks. Some children had side effects related to selumetinib, although these were generally manageable. Results from the NF1 caregivers experience study showed caregivers of children with plexiform neurofibromas face significant impacts in physical, psychological, economic, and social aspects. These effects often result in a loss of productivity and difficulties with daily activity. What do the results of the study mean?: Children with NF1 who have symptomatic, inoperable plexiform neurofibromas can benefit from selumetinib treatment. Selumetinib is generally well-tolerated, but it is important to monitor side effects during treatment. Caring for a child with NF1 and symptomatic, inoperable plexiform neurofibromas has a significant impact on family members and others providing daily care. This highlights the importance of improving treatment and quality of life for both children with the condition and their caregivers.
- 1 March 2025
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 14 (3) , e240184
Open AccessSelumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary
What is this summary about?: Neurofibromatosis type 1 (also called NF1) is a rare genetic condition. It causes a range of symptoms that develop from childhood onwards and worsen over time. Some children with NF1 develop non-cancerous nerve tumors called plexiform neurofibromas. Plexiform neurofibromas can grow large and compress nearby tissues. This can cause severe pain, reduced movement, vision and hearing loss, and other medical problems. Some children can have plexiform neurofibromas removed surgically. Most children have tumors that cannot be removed by surgery (known as inoperable tumors). Children with inoperable plexiform neurofibromas can receive a medicine called selumetinib. This plain language summary includes important findings from two selumetinib studies in children with NF1 and inoperable plexiform neurofibromas: The SPRINT selumetinib studies are part of a clinical study program that looked at how well selumetinib works in treating children with symptomatic, inoperable plexiform neurofibromas. The SPRINT studies program included the first studies of this medicine done in children, called phase 1 and phase 2 studies. For the phase 2 study, some children had severe symptoms and some children did not. The group of children with severe symptoms is called group 1, and their results are included in this summary. The researchers monitored the participating children for up to 5 years in a long-term study to better understand how the treatment works over time. The NF1 caregivers experience study is a related study where caregivers shared their experiences of caring for children with NF1and plexiform neurofibromas. What were the results?: A total of 74 children took part in the SPRINT phase 1 and phase 2 (group 1) study. Their ages ranged from 3 to 18.5 years, and their average age was 10.3 years. After more than 4 years of treatment, around 70% of the children (52 out of 74) had smaller tumors. For most children, the responses lasted beyond 1 year. There was a significant and lasting reduction in the intensity of the children’;s tumor pain, noticeable as early as 2 months after starting the treatment. After 12 months, children reported their pain dropped from an average score of 2.2 to 0.6 and stayed low at 0.58 over 4 years. There was also an improvement in how much their pain affected the children's ability to do daily tasks. Some children had side effects related to selumetinib, although these were generally manageable. Results from the NF1 caregivers experience study showed caregivers of children with plexiform neurofibromas face significant impacts in physical, psychological, economic, and social aspects. These effects often result in a loss of productivity and difficulties with daily activity. What do the results of the study mean?: Children with NF1 who have symptomatic, inoperable plexiform neurofibromas can benefit from selumetinib treatment. Selumetinib is generally well-tolerated, but it is important to monitor side effects during treatment. Caring for a child with NF1 and symptomatic, inoperable plexiform neurofibromas has a significant impact on family members and others providing daily care. This highlights the importance of improving treatment and quality of life for both children with the condition and their caregivers.